As of May 27, 2025, Aclaris Therapeutics Inc (ACRS) reports a ROE (Return on Equity) of -84.90%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Aclaris Therapeutics Inc's ROE (Return on Equity)
Over recent years, Aclaris Therapeutics Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | -84.90% |
| 2023-12-31 | -56.29% |
| 2022-12-31 | -43.98% |
| 2021-12-31 | -46.06% |
| 2020-12-31 | -135.33% |
This slight downward trend highlights how Aclaris Therapeutics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Aclaris Therapeutics Inc's ROE (Return on Equity) to Peers
To better understand Aclaris Therapeutics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Aclaris Therapeutics Inc (ACRS) | -84.90% |
| Cara Therapeutics Inc (CARA) | 1542.93% |
| Redhill Biopharma Ltd (RDHL) | 1155.92% |
| Urovant Sciences Ltd (UROV) | 252.98% |
| Revance Therapeutics Inc (RVNC) | 213.71% |
| Seelos Therapeutics Inc (SEEL) | 113.05% |
Compared to its competitors, Aclaris Therapeutics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.